NCT07164586

Brief Summary

Introduction: The monitoring of respiratory patterns is crucial in the management of respiratory diseases, but in many cases, it still relies on subjective and visual assessment. The use of healthcare technologies based on artificial intelligence (AI) can, in these contexts, enhance clinical decision-making by providing a more objective and accurate analysis. Given the high prevalence of acute and chronic respiratory diseases, the implementation of a device capable of detecting variables such as flow, volume, and time becomes a priority for more effective diagnosis and therapeutic planning. Objective: Evaluate the accuracy, validity, and usability of an intelligent system for monitoring the respiratory pattern of patients at risk of acute respiratory failure. Methods: This is a prospective cohort study that will be conducted in the emergency departments of the Otávio de Freitas Hospital and Urgent Care Units (UPAs). The sample will consist of volunteers of both sexes, aged 18 years or older, breathing spontaneously, and suspected of having acute respiratory failure. Screening will be performed daily, where sociodemographic information, blood gas data, laboratory results, and additional information will be collected. When indicated, pulmonary function tests, respiratory muscle strength tests, and diaphragmatic ultrasound will be conducted. Respiratory pattern data will be collected using the Respiratory Diagnostic Assistant. Statistical analysis will be performed according to data modeling and treatment, adopting significant differences with p \< 0.05. Expected Results: It is expected that the results of this study will provide quantitative data on the respiratory pattern of volunteers suspected of having acute respiratory failure. This information will be integrated into a database with the aim of enhancing the device's ability to detect changes in respiratory patterns, as well as contributing to the development of artificial intelligence capable of accurately and efficiently identifying these changes.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2025

Shorter than P25 for all trials

Geographic Reach
1 country

3 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 18, 2025

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

August 21, 2025

Completed
20 days until next milestone

First Posted

Study publicly available on registry

September 10, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 28, 2025

Completed
24 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 22, 2025

Completed
Last Updated

September 10, 2025

Status Verified

September 1, 2025

Enrollment Period

3 months

First QC Date

August 21, 2025

Last Update Submit

September 1, 2025

Conditions

Keywords

Respiratory MechanicsRespiratory DiseasesTechnological InnovationIntelligent SystemsAcute Respiratory Failure

Outcome Measures

Primary Outcomes (2)

  • Respiratory Pattern Assessment using Respiratory Diagnostic Assistant (RDA)

    The Respiratory Diagnostic Assistant (RDA) is a portable, non-invasive device providing qualitative and quantitative data on respiratory variables. Participants are assessed seated (or supine 30º if needed) through three stages: baseline respiration (3 min), slow vital capacity, and inspiratory capacity maneuvers (3 repetitions each, 1-min intervals). Measured variables include respiratory rate (breaths per minute), mean inspiratory/expiratory flow (L/s), TI (s), TE (s), tidal volumes (mL), minute volumes (L/min). Data are analyzed qualitatively and quantitatively, with graphical representation. Respiratory patterns may be compared with conventional monitoring (pulse oximetry, respiratory rate, or arterial blood gas).

    For an average period of four months, until the conclusion of the studies

  • System Usability Scale

    The System Usability Scale (SUS) is a 10-item standardized questionnaire designed to assess usability and user experience of systems. Participants respond on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree), generating a total score ranging from 0 to 100. In this study, the SUS will evaluate participants' perceptions of the intelligent respiratory monitoring system, including ease of use, learnability, and satisfaction. The instrument is used solely for data collection and does not constitute a therapeutic intervention."

    For an average period of four months, until the conclusion of the studies

Secondary Outcomes (7)

  • Peak Expiratory Flow (PEF) Data

    For an average period of four months, until the conclusion of the studies

  • Diaphragmatic Excursion Assessment

    For an average period of four months, until the conclusion of the studies

  • Self-reported Dysfunctional Breathing and Hyperventilation Symptoms (Nijmegen Questionnaire)

    For an average period of four months, until the conclusion of the studies

  • Sociodemographic and Clinical Baseline Data Collection (Patient Identification Questionnaire)

    Completed once per participant at baseline to collect sociodemographic and basic clinical data

  • Pulmonary Function Assessment (Spirometry)

    For an average period of four months, until the conclusion of the studies

  • +2 more secondary outcomes

Other Outcomes (1)

  • Perceived Respiratory Effort and Breathlessness (Borg Scale)

    For an average period of four months, until the conclusion of the studies

Study Arms (2)

Control Group - Healthy Individuals

Individuals without pulmonary impairment as confirmed through comprehensive respiratory assessment including pulmonary function testing (spirometry), respiratory muscle strength evaluation (manometry), and thorough medical history screening for previous respiratory or cardiopulmonary diseases. Participants must demonstrate normal lung function parameters, adequate respiratory muscle strength, and absence of any history of chronic obstructive pulmonary disease, asthma, pneumonia, tuberculosis, or other conditions that could compromise respiratory function

Diagnostic Test: Respiratory Pattern MonitoringDiagnostic Test: Diaphragmatic ExcursionDiagnostic Test: Respiratory Muscle StrengthDiagnostic Test: Pulmonary Function AssessmentOther: Data Acquisition SystemOther: Borg ScaleOther: Patient Identification QuestionnaireDiagnostic Test: Peak Expiratory Flow (PEF) Measurement

Intervention Group - Patients at Risk of Acute Respiratory Failure

This group will consist of adult patients (≥18 years), of both sexes, seen in emergency departments, urgent care units, or walk-in clinics associated with the study, who are in spontaneous breathing, with or without supplemental oxygen, and present with respiratory complaints associated with the risk of acute respiratory failure. Participants will be assessed using a sociodemographic and clinical form, including their documented medical diagnosis. Respiratory pattern monitoring will be conducted using the Respiratory Diagnostic Assistant (RDA) device, diaphragmatic mobility will be evaluated via ultrasonography, and muscle electrical activity will be assessed through surface electromyography. When clinically appropriate, pulmonary function tests and respiratory muscle strength assessments will also be performed, in accordance with the recommendations of the American Thoracic Society and the European Respiratory Society.

Diagnostic Test: Respiratory Pattern MonitoringDiagnostic Test: Diaphragmatic ExcursionDiagnostic Test: Respiratory muscle electrical activityDiagnostic Test: Respiratory Muscle StrengthDiagnostic Test: Pulmonary Function AssessmentOther: Data Acquisition SystemOther: Nijmegen QuestionnaireOther: System Usability Scale (SUS)Other: Borg ScaleOther: Patient Identification QuestionnaireDiagnostic Test: Peak Expiratory Flow (PEF) Measurement

Interventions

Respiratory pattern assessment and continuous monitoring will be conducted utilizing the Respiratory Diagnostic Assistant, a device capable of providing comprehensive quantitative evaluation of respiratory variables including frequency, volume, flow rates, inspiratory/expiratory timing parameters, and respiratory entropy analysis, as well as qualitative analysis of respiratory pattern curves for volume and flow dynamics, incorporating entropy measurements for assessment of respiratory pattern complexity and variability.

Control Group - Healthy IndividualsIntervention Group - Patients at Risk of Acute Respiratory Failure

Diaphragmatic mobility assessment will be conducted using diaphragmatic ultrasonography, a method capable of providing comprehensive quantitative evaluation of diaphragmatic excursion parameters including range of motion, contraction velocity, muscle thickening during inspiration and expiration, as well as qualitative analysis of diaphragm muscle morphology and echogenicity, incorporating craniocaudal displacement measurements for assessment of contractile function and early detection of diaphragmatic dysfunction."

Control Group - Healthy IndividualsIntervention Group - Patients at Risk of Acute Respiratory Failure

espiratory muscle electrical activity assessment will be conducted using surface electromyography, a method capable of providing comprehensive quantitative evaluation of muscle activation parameters including electrical signal amplitude, firing frequency, muscle recruitment patterns during inspiration and expiration, as well as qualitative analysis of synchronization and coordination between respiratory muscles, incorporating Root Mean Square (RMS) measurements and spectral analysis for assessment of respiratory neuromuscular function and detection of muscle fatigue.

Intervention Group - Patients at Risk of Acute Respiratory Failure

Respiratory muscle strength assessment will be conducted using manovacuometry, a method capable of providing comprehensive quantitative evaluation of respiratory muscle force parameters including maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP), as well as qualitative analysis of contractile capacity and muscle endurance, incorporating peak pressure measurements and performance indices for assessment of global respiratory muscle function and early detection of muscle weakness

Control Group - Healthy IndividualsIntervention Group - Patients at Risk of Acute Respiratory Failure

Pulmonary function assessment will be conducted using spirometry, a method capable of providing comprehensive quantitative evaluation of respiratory function parameters including forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC ratio, and forced expiratory flow 25-75% (FEF25-75%), as well as qualitative analysis of flow-volume and volume-time curves, incorporating lung capacity and volume measurements for assessment of respiratory mechanics and early detection of obstructive and restrictive ventilatory disorders."

Control Group - Healthy IndividualsIntervention Group - Patients at Risk of Acute Respiratory Failure

The PowerLab C is a biomedical data acquisition system used as an auxiliary tool for physiological monitoring. In this study, it will be employed to collect respiratory signals and diaphragmatic excursion data through specific sensors, integrated with LabChart software for data visualization and analysis. The device is not considered an investigational intervention, but a supporting tool for data collection.

Control Group - Healthy IndividualsIntervention Group - Patients at Risk of Acute Respiratory Failure

The Nijmegen Questionnaire is a standardized self-report instrument designed to assess symptoms related to dysfunctional breathing and hyperventilation. In this study, it will be administered to evaluate respiratory symptoms and their impact on participants' daily life. The questionnaire is used solely for data collection and is not considered a therapeutic intervention.

Intervention Group - Patients at Risk of Acute Respiratory Failure

The System Usability Scale (SUS) is a standardized questionnaire used to evaluate the usability and user experience of systems and devices. In this study, it will be applied to assess participants' perceptions of the usability of an intelligent respiratory monitoring system. The SUS will be used solely as a data collection tool and does not constitute a therapeutic intervention.

Intervention Group - Patients at Risk of Acute Respiratory Failure

The Borg Scale is a standardized self-report instrument used to assess perceived exertion and breathlessness during physical activity. In this study, it will be applied to evaluate participants' perception of respiratory effort. The scale is used solely for data collection and is not considered a therapeutic intervention.

Control Group - Healthy IndividualsIntervention Group - Patients at Risk of Acute Respiratory Failure

The Patient Identification Questionnaire is a standardized form used to collect sociodemographic and basic clinical information from participants, such as age, sex, and medical history. In this study, it will serve solely for data collection and will not constitute a therapeutic intervention.

Control Group - Healthy IndividualsIntervention Group - Patients at Risk of Acute Respiratory Failure

Peak Expiratory Flow (PEF) measurement is a rapid and noninvasive method to assess the maximum expiratory volume a participant can achieve after a full inhalation. In this study, participants will be seated upright and use a mouthpiece connected to a peak flow meter. After a deep inspiration, they will exhale forcefully, and three measurements will be taken with at least one minute between attempts; the highest value will be recorded. PEF values provide an objective measure of airflow limitation, correlate with asthma symptoms, and will be used solely for data collection, not as a therapeutic intervention

Control Group - Healthy IndividualsIntervention Group - Patients at Risk of Acute Respiratory Failure

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The population will be composed of healthy participants and patients awaiting care or receiving emergency care in hospital emergency departments and emergency care units affiliated with the study, who are in spontaneous breathing, with or without oxygen therapy, at risk of acute respiratory failure.

You may qualify if:

  • Volunteers and patients of both sexes
  • Age greater than or equal to 18 years
  • Spontaneous breathing
  • Patients awaiting care in emergency departments, urgent care units, and emergency services
  • Presence of complaints associated with respiratory difficulty
  • Patients at risk of acute respiratory failure
  • With or without supplemental oxygen therapy
  • Ability to remain without oxygen therapy for a minimum period of three minutes

You may not qualify if:

  • Psychomotor agitation
  • Anxiety validated through qualitative assessment
  • Poor mask fit and/or presence of air leaks
  • Facial fracture or trauma
  • Refusal to participate in the study or sign the informed consent form
  • Contraindications to performing manovacuometry and spirometry, when appropriate, according to the recommendations of the American Thoracic Society and European Respiratory Society (Graham et al., 2019)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Emergency Care Unit from Engenho Velho

Jaboatão dos Guararapes, Pernambuco, 54160-000, Brazil

Location

Department of Physical Therapy

Recife, Pernambuco, 50740-560, Brazil

Location

Otávio de Freitas Hospital

Recife, Pernambuco, 50920-640, Brazil

Location

Related Links

MeSH Terms

Conditions

Respiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

August 21, 2025

First Posted

September 10, 2025

Study Start

August 18, 2025

Primary Completion

November 28, 2025

Study Completion

December 22, 2025

Last Updated

September 10, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will share

Individual participant data will be pseudonymized and shared only after publication of the study results through REDCap repositories, with DOI assignment and a Creative Commons license (CC BY-NC-ND). Demographic, clinical, respiratory, and processed datasets supporting the published analyses will be made available, excluding any information that could directly or indirectly identify participants. Access may be open or granted upon justified request, depending on the sensitivity of the data, and any transfers will be governed by formal data use agreements. Data will be curated, version-controlled, and preserved in institutional and secure scientific repositories for at least five years after publication, in strict compliance with the Brazilian General Data Protection Law (LGPD), institutional policies, and all applicable ethical approvals.

Shared Documents
STUDY PROTOCOL, SAP, ANALYTIC CODE
Time Frame
Individual participant data (IPD) and supporting documentation will be available starting at the time of publication of the study's main results. Access will remain open or granted upon justified request for at least five years after publication. After this period, continued availability will depend on institutional policies, repository conditions, and the relevance of the dataset for future research.
Access Criteria
Access will remain open or granted upon justified request for at least five years after publication.

Locations